Journals / JAREM / 2022 / Cilt: 12 - Sayı: 1

Retrospective Evaluation of Risk Factors for the Development of Invasive Fungal Infections in Immunosuppressed Patients

İmmünsüprese Hastalarda İnvaziv Fungal Enfeksiyon Gelişimindeki RiskFaktörlerinin Retrospektif Değerlendirilmesi

Journal
JAREM
Pages
21–27
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

No significant difference was found in other parameters (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The incidence of invasive fungal infection (IFI) is increasing in immunosuppressed patients.
📊
Key Findings & Data:Methods: This retrospective study included 84 adult patients with IFI diagnosis between January 1, 2012, and April 1, 2014, at our hospital.
💡
Conclusion & Impact:No significant difference was found in other parameters (p
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: The incidence of invasive fungal infection (IFI) is increasing in immunosuppressed patients. Thus, this study aimed to compare the types and the distribution of IFI, determine the probable risk factors in its development, and assess the mortality and underlying diseases among patients with hematological malignancies and those with non-hematological immunosuppression. Methods: This retrospective study included 84 adult patients with IFI diagnosis between January 1, 2012, and April 1, 2014, at our hospital. Results: The distribution of cases was documented as follows: 58 (69.0%) patients were proven with IFI, 12 (14.3%) with probable IFI, and 14 (16.7%) with possible IFI. Patient distributions with proven IFI were as follows: 91.4% (53/58) with invasive candidiasis (IC), 5.2% (3/58) with invasive pulmonary aspergillosis (IPA), 1.7% (1/58) with nasopharyngeal invasive fungal involvement, and 1.7% (1/58) with invasive fungal involvement in the colon. All cases of probable and possible IFE (26/26, 100%) were determined as IPA. The following is previously known risk factors for IFI development were evaluated for both groups: immunosuppressive drug usage, renal replacement therapy requirement, mechanical ventilation requirement, presence of a central venous catheter, presence of a urinary catheter, presence of gastrointestinal catheter, mucositis/diarrhea/ileus history, malnutrition, blood product transfusion, bacterial infection, antibacterial treatment, length of hospital and intensive care unit stay, and duration of neutropenia. The immunosuppressive drug usage and neutropenia duration were found to be statistically significant between the hematologic malignancy and nonhematologic immunosuppressive groups. No significant difference was found in other parameters (p

Özet

Amaç: İmmünosüpresif hastalarda invazif fungal enfeksiyon (İFE) görülme sıklığı giderek artmaktadır. Çalışmamızın amacı hematolojik maligniteli ve non-hematolojik immünsüpresif hasta gruplarında saptanan İFE tiplerini ve dağılımını karşılaştırmak; İFE gelişiminde olası risk faktörlerini saptamak; mortaliteyi değerlendirmek; altta yatan hastalıkları karşılaştırmaktır. Yöntemler: Bu retrospektif çalışmaya, hastanemizde 01 Ocak 2012 ve 1 Nisan 2014 tarihleri arasında İFE tanısı almış, 84 erişkin hasta dahil edildi. Bulgular: Olguların dağılımı; kanıtlanmış İFE (58/84, %69), olası İFE (12/84, %14,2), mümkün İFE (14/84, %16,6) olarak tespit edildi. Kanıtlanmış İFE olgularının %91,3’ü (53/58) invazif kandidiyazis (İK), %5,1’i (3/58) ise invaziv pulmoner aspergillozis (İPA), nazofaringeal invazif fungal tutulum (1/58, %1,7) ve kolonda invazif fungal tutulum (1/58, %1,7) idi. Olası ve mümkün İFE hastalarının hepsi (26/26, %100) İPA olarak saptandı. Bilinen İFE risk faktörleri olan immünsüpresif tedavi kullanımı, renal replasman tedavisi ihtiyacı, mekanik ventilasyon ihtiyacı, santral venöz kateter mevcudiyeti, üriner kateter mevcudiyeti, GİS kateter mevcudiyeti, mukozit/diyare/ileus öyküsü, malnutrisyon, kan ürünü transfüzyonu, bakteriyel enfeksiyon, antibakteriyel tedavi, hastane ve yoğun bakım yatış süreleri, nötropeni süresi tüm hastalarda irdelendi. Hematolojik malignite ve non-hematolojik immünosüpresif gruplar arasında, immünosüpresif tedavi kullanımı ve nötropeni süresi istatistiksel olarak anlamlı bulundu. Bunun dışındaki parametreler için iki grup arasında anlamlı fark bulunamadı (p

🔖

Cite This Article

OK, M. A., ÖZALP, O., ARSLAN, A. H., YEŞİLKAYA, A. (2022). Retrospective Evaluation of Risk Factors for the Development of Invasive Fungal Infections in Immunosuppressed Patients. JAREM, Cilt: 12 - Sayı: 1, 21–27. https://ajindex.com/articles/558136

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Montagna MT, Lovero G, Coretti C, Martinelli D, Delia M, De Giglio, et al. SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients. Infection 2014; 42: 141-51
  2. Grossi PA, Gasperina DD, Barchiesi F, Biancofiore G, Carafiello G, Gasperi AD, et al. Italian guidelines for diagnosis, prevention, and treatment of invasive fungal infections in solid organ transplant recipients. Transplant Proc 2011; 43: 2463-71
  3. Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50: 1101-11
  4. Von Lilienfeld-Toal M, Wagener J, Einsele H, Cornely OA, Kurzai O. Invasive Fungal Infection. Dtsch Arztebl Int 2019; 116: 271-8
  5. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21
  6. Lionakis MS. Primary immunodeficiencies and invasive fungal infection: when to suspect and how to diagnose and manage. Curr Opin Infect Dis 2019; 32: 531-7
  7. Tejeda MI, Salso S, Barberán J. Aspergilosis pulmonar en pacientes no neutropénicos [Invasive pulmonary aspergillosis in non-neutropenic patients]. Rev Esp Quimioter 2016; 29 Suppl 1: 56-8
  8. Paramythiotou E, Frantzeskaki F, Flevari A, Armaganidis A, Dimopoulos G. Invasive fungal infections in the ICU: how to approach, how to treat. Molecules 2014; 19: 1085-119
  9. Ben-Ami R, Halaburda K, Klyasova G, Metan G, Torosian T, Akova M. A multidisciplinary team approach to the management of patients with suspected or diagnosed invazive fungal disease. J Antimicrob Chemother 2013; 68 Suppl 3: 25-33
  10. Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, ArikanAkdagli S, et al. ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 2012; 18 Suppl 7: 53-67
  11. Ascioglu S, Rex JH, De Pauw B, Bennett JE, Bille J. Defining oppotunistic invasive fungal infections in immunocompromised patients with cancer and